Long-Term Follow-up Study

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Caribou Biosciences, Inc.
Study ID
NCT05332054
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Caribou-sponsored investigational therapy — BIOLOGICAL
    N/A this is an observational study

Study Details

This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.

Key Dates

Start date
Mar 16, 2022
Status verified
Mar 2026
Primary completion
Dec 31, 2041
Completion
Dec 31, 2041

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: Patients who received IP in a Caribou-sponsored, special access program or IIT and provided informed
    consent for the LTFS

Primary Outcome Measure

Incidence of targeted NSAEs [ Time Frame: 15 Years ]

Locations (31)

FacilityCityStateZIPSite coordinators
University of AlabamaBirminghamAlabama35233-
Banner MD Anderson Cancer CenterGilbertArizona85234-
Honor Health Research InstituteScottsdaleArizona85258-
University of California IrvineIrvineCalifornia92868-
University of California San DiegoLa JollaCalifornia92093-
Colorado Blood Cancer InstituteDenverColorado80218-
University of ColoradoDenverColorado80045-
University of MiamiMiamiFlorida33136-
AdventHealth Medical Group Blood & Marrow Transplant at OrlandoOrlandoFlorida32804-
Blood & Marrow Transplant Group of GeorgiaAtlantaGeorgia30342-
Augusta University/Georgia Cancer CenterAugustaGeorgia30912-
University of Iowa Hospitals & ClinicsIowa CityIowa52242-
University of KentuckyLexingtonKentucky40536-
Norton Cancer InstituteLouisvilleKentucky40207-
Regional Cancer Care Associates - HackensackHackensackNew Jersey07601-
Atlantic Health System Cancer CareMorristownNew Jersey07960-
Icahn School of Medicine at Mt. SinaiNew YorkNew York10029-
Weill Cornell MedicineNew YorkNew York10021-
Montefiore Medical CenterThe BronxNew York10467-
Levine Cancer CenterCharlotteNorth Carolina28204-
Oncology Hematology CareCincinnatiOhio45242-
Cleveland ClinicClevelandOhio44195-
University of PennsylvaniaPhiladelphiaPennsylvania19104-
Sarah Cannon Research Institute - TriStar HealthNashvilleTennessee37203-
Baylor Research InstituteDallasTexas75246-
University of Texas SouthwesternDallasTexas75235-
MD Anderson Cancer CenterHoustonTexas77030-
Huntsman Cancer Institute at the University of UtahSalt Lake CityUtah84112-
Virginia Commonwealth UniversityRichmondVirginia23284-
Fred Hutchinson Cancer CenterSeattleWashington98109-
Medical College of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of Alabama· Birmingham, ALBanner MD Anderson Cancer Center· Gilbert, AZHonor Health Research Institute· Scottsdale, AZUniversity of California Irvine· Irvine, CAUniversity of California San Diego· La Jolla, CAColorado Blood Cancer Institute· Denver, CO

Related Studies